



Welcome!



Dear Attendees,

I would like to welcome you to Duke Dermatology's Annual Research Symposium of the Pinnell Center for Investigative Dermatology. This symposium has been an annual event commemorating Dr. Sheldon Pinnell and his commitment to investigation and innovation in dermatology.

Our 10th symposium will focus on "ImmunoOncology: Tumors, Treatments, and Toxicities." We look forward to learning from distinguished visiting professors, as well as Duke faculty and trainees. We are also excited to launch our inaugural research poster competition where trainees will showcase their accomplishments.

We are excited to continue celebrating Dr. Pinnell's vision to advance investigative dermatology and Duke Dermatology.

Sincerely,

A handwritten signature in blue ink that reads "Suephy Chen". The signature is written in a cursive, flowing style.

Suephy C. Chen, MD, MS
Chair, Duke Department of Dermatology

Pinnell Center for Investigative Dermatology 2024 Annual Symposium

Friday, September 6, 2024

8 AM - 5 PM

Duke University School of Medicine

Trent Semans Center

The Great Hall Room

Presented by:

Duke Department of Dermatology


Symposium Co-Chairs:

Jennifer Yunyan Zhang, PhD

Melodi Javid Whitley, MD, PhD



Invited Speakers



Niroshana Anandasabapathy, MD, PhD
Weill Cornell Medicine

Dr. Niroshana Anandasabapathy is an Associate Professor of Dermatology, Microbiology and Immunology at Weill Cornell Medicine. She is an investigative physician scientist formally trained in clinical investigation, cancer biology, cellular immunology, and clinical dermatology. Her research investigates how tissue immune programming governs maintenance of homeostasis, the relevance of such programs to establishing protective immunity, including immunity against melanoma skin cancer and other cancers.



Michael Sargen, MD
National Cancer Institute, National Institutes of Health

Michael Sargen is an Assistant Clinical Investigator in the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. He also is a Dermatopathologist in the Laboratory of Pathology, National Cancer Institute and serves as Principal Investigator for the NCI Familial Melanoma Study and the NCI Spitzoid Tumor Study. His research combines genomic and epidemiologic methodologies to understand the etiology of cancer



Eugene R. Semenov, MD, MA
Massachusetts General/ Harvard Medical School

Eugene R. Semenov, MD, MA is an Assistant Professor in Dermatology and Co-Director of the Oncodermatology Program at the Massachusetts General Hospital and Harvard Medical School with extensive experience in clinical informatics, health economics, and public health research. His clinical experience includes cutaneous oncology with a focus on melanoma and supportive oncodermatology.

Internal Speakers

Duke University School of Medicine:

Faculty

Suephy C. Chen, MD, MS, Professor and Chair, Duke Dermatology

Brent Hanks, MD, PhD, Associate Professor of Duke Medicine

Mikhail Nikiforov, PhD, Professor of Duke Pathology

Michelle Pavlis, MD, Associate professor of Duke Dermatology

Trainee

Matthew Draelos, MD, PhD, 2 + 2 Resident of Duke Dermatology

Meng Jiao, PhD, Postdoc of Duke Dermatology

Wanying Miao, MD, PhD, Postdoc of Duke Dermatology

Agenda

7:30am	Continental Breakfast
8:00	Welcome Suephy C. Chen, MD, MS Professor and Chair of Duke Dermatology
8:10	Cutaneous toxicities of immune checkpoint inhibitors Sabrina Shearer, MD Duke Dermatology
8:30	Shared mechanisms of Anti-PD1 efficacy in tumor, and toxicity in tissue Niroshana Anandasabapathy, MD, PhD Weill Cornell Medicine
9:20	Melanoma in Veterans: clinical characteristics, genetics, and real-world effectiveness of immunotherapy Michelle Pavlis, MD Duke Dermatology
9:40	Break
9:55	Dermatology in the era of Immunotherapy: from skin toxicities to melanoma prognostication Eugene Semenov, MD, MA Massachusetts General, Harvard Medical School
10:50	Deciphering the etiology of skin malignancies through large-scale epidemiologic and multi-omic profiling Michael Sargen, MD National Cancer Institute, National Institutes of Health
11:40	The challenges of clinical margin assessment Matthew Draelos, MD, PhD Duke Dermatology
11:55	Lunch
1:00	Anti-leprosy drug clofazimine: an inhibitor of AhR signaling and a potent immunomodulator Mikhail Nikiforov, PhD Duke University
1:50	Targeting PCSK9 to overcome the resistance of LKB1-deficient lung cancer to immune checkpoint blockade immunotherapy Meng Jiao, PhD Duke University

2:05	Targeting regulatory T-cells to enhance immunity against melanoma Wanying Miao, MD, PhD Duke University
2:20	Role of Inflammation and Stress in Melanoma Immune Evasion, Relapse, and Immunotherapy Resistance Brent Hanks, MD, PhD Duke University
3:10	Closing Remarks
3:15-5:00	Poster Session

Overview

The Pinnell Center for Investigative Dermatology will hold its 9th annual symposium. This year's theme is, "ImmunoOncology: Detection, Treatments, Mechanisms, and Toxicities."

The purpose of the symposium is to articulate updates in basic, translational and clinical science research of the rapidly evolving field of cutaneous oncology, with a special focus on the role of the immune system in tumor risk, progression, and treatment. We will also explore emerging immunotherapeutic agents, as well as cutaneous side effects of current treatments.

Target Audience

Clinical care teams, including physicians, residents, and fellows, as well as basic science researchers and trainees of all levels interested in ImmunoOncology.

Course Goals and Objectives

The intent of this conference is to inform the clinical care team the current and emerging treatments and their side effects, and the bench-side researchers the clinical needs and barriers to treatment success.

At the conclusion of this activity, participants should be able to:

1. Articulate scientific updates in the fields of cutaneous oncology and immunotherapy.
2. Gain expanded knowledge about ImmunoOncology, including tumor risks, treatments, and toxicities, as well as mechanisms of tumor progression and resistance.
3. Describe approaches for cancer research and drug development

Faculty Listing

Course Director: Suephy C. Chen, MD, MS, Duke University

Symposium Co-Chairs: Melodi Javid Whitley, MD, PhD, Duke University; Jennifer Yunyan Zhang, PhD, Duke University

Accreditation

In support of improving patient care, Duke University Health System Department of Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.



Credit Designation

Duke University Health System Department of Clinical Education and Professional Development designates this jointly accredited activity for a maximum of 5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Obtaining Course Credit

In order to receive credit, please use the QR code to enter your name and email address. After the activity, this information will be turned into the Duke Continuing Education Office. You will then receive an email from Duke Continuing Education that will provide you with instructions for obtaining your credits and printing your certificate.

Conflict of Interest Policy

Duke University Health System Clinical Education and Professional Development has implemented a process to resolve any potential conflicts of interest for each continuing education activity in order to help ensure content objectivity, independence, fair balance, and the content that is aligned with the interest of the public.

The Pinnell Center Fund

Established in 2013, the Pinnell Center for Investigative Dermatology was named in honor of Sheldon R. Pinnell, MD, (1937-2013), former J. Lamar Calloway Professor of Dermatology and Chief, Division of Dermatology. The Center's purpose includes the following:

- Advance discovery and translation in skin biology and disease
- Provide access to critical difficult to duplicate technologies and resources to facilitate studies at the gene, cellular, tissue and animal levels
- Advance our understanding of skin biology and pathogenesis and treatment of skin disease
- Provide support for early career investigators through initial funding
- Provide support for post-doctoral fellow training
- Fund innovative proposals and new projects focused on translational research leading to new therapies for skin disease
- Provide enrichment of the investigative community through regular seminar series, development of core facilities and laboratories, and support for translational and clinical research

The Pinnell Center Fund was created in 2013 to support the needs of the Pinnell Center. Your generous support is greatly appreciated.



<https://duke.is/8/j375>